Pharmacogenomics Market Analysis 2026

Market Dynamics of The Pharmacogenomics Market

Key Drivers for The Pharmacogenomics Market

• The increasing number of chronic diseases is driving the growth of the pharmacogenomics market.

The market for pharmacogenomics is mostly driven by the increased frequency of several illnesses, including cancer, neurological disorders, mental ailments, and cardiovascular diseases. The increasing prevalence of chronic disease conditions worldwide has led to a growing demand for more individualized and efficient treatment plans that address the various genetic variables impacting each patient's response to medicine.
For instance, in September 2023, according to the World Health Organization, there were 41 million deaths, which is 74% of those caused by non-communicable diseases (NCDs) or chronic diseases every year globally. There were 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths from diabetes. 
Source:(https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases)

For instance, in June 2023, The NHS will conduct a pilot study to determine if it is feasible to provide pharmacogenomics testing for patients using statins, antidepressants, and proton pump inhibitors (PPIs). To ensure patients are taking the proper prescription and are not at risk for adverse effects when they start using a specific antidepressant, a fresh statin, or a proton pump inhibitor, the pilot will screen them. 
Source:(https://pharmaceutical-journal.com/article/news/pharmacogenomic-testing-pilot-to-start-in-general-practice-from-june-2023)
The increasing number of chronic diseases require pharmacogenomics to offer a personalized approach for the treatment of chronic diseases Considering the individual genetic differences that affect a drug's reaction, hence driving the growth of the pharmacogenomics market.

• Increasing collaborations among research institutes drive the growth of the pharmacogenomics market 

Increasing collaborations among research institutes drive the growth of the pharmacogenomics market by fostering knowledge exchange, resource sharing, and accelerated research progress. Through collaborative efforts, institutes can pool expertise, data, and infrastructure, facilitating more comprehensive studies and faster advancements in understanding genetic influences on drug response. This synergy enables the identification of new biomarkers, drug targets, and personalized treatment strategies, thereby enhancing the efficiency and efficacy of pharmacogenomics approaches in healthcare. 
For instance, in August 2020, the University of California, San Francisco (UCSF), a health science university, expanded its pharmacogenomics efforts by launching a new collaboration with Tampa General Hospital and its pharmacy team that will allow clinicians to tailor medications based on a patient’s genetic makeup. Plans include developing clinical decision support tools in the electronic health record (EHR) to support clinicians in interpreting results and guiding treatment options in the presence of pharmacogenetic data.
source:(https://hscweb3.hsc.usf.edu/blog/2020/08/25/taneja-college-of-pharmacy-expands-personalized-medicine-in-collaboration-with-tampa-general-hospital/)

For instance, in March 2024 Western New England University College of Pharmacy and Health Sciences partnered with the American Pharmacogenomics Association to Enhance the Master of Science in Pharmacogenomics program. This collaboration marks a significant step forward in advancing education and research in the field of pharmacogenomics, where the study of how an individual's genetic makeup influences their response to medications is paramount.
Source:(https://wne.edu/news/2024/03/wne-apgxa-partnership.cfm)
Thus increasing collaboration with research institutes fosters technology innovations and significantly drives the growth of the pharmacogenomics market.

Restraint Factor for The Pharmacogenomics Market
 

• The shortage of skilled healthcare professionals restrains the market growth of pharmacogenomics. 

The shortage of skilled healthcare professionals capable of performing pharmacogenomics diagnostic tests and the lack of pharmacogenomics information integrated into electronic healthcare systems are anticipated to hinder market growth. Without enough trained personnel, the adoption and implementation of pharmacogenomics testing may be slow, limiting its accessibility and utilization. Additionally, the absence of pharmacogenomics data in electronic systems used by healthcare professionals could impede the seamless integration of genetic information into clinical decision-making processes, potentially leading to suboptimal treatment outcomes and slower market adoption. Addressing these challenges through education and technological integration is crucial for overcoming barriers to market growth in pharmacogenomics.
For instance, an article published in Frontiers, a publisher peer-reviewed open-access scientific journal, in September 2021, healthcare professionals lack adequate training and education in pharmacogenomics and they are concerned about the absence of evidence-based clinical guidelines
Source:(https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.724311/full)
Therefore, the market expansion is anticipated to be hampered by a shortage of qualified healthcare workers who can execute pharmacogenomics diagnostic tests and by a dearth of pharmacogenomics data in the electronic systems that healthcare professionals utilize. 

Impact of Covid-19 on The Pharmacogenomics Market

The pharmacogenomics market was negatively affected by the COVID-19 pandemic because it forced the suspension of clinical studies, medication development, and diagnostic methods for illnesses other than COVID-19. According to a research paper released by PubMed in December 2021, the COVID-19 pandemic significantly decreased the number of procedures needed to detect cancer, which in turn led to a decrease in the number of new diagnoses throughout the United States. The number of new cancer diagnoses dropped from 13% to 23%, indicating that COVID-19 had a detrimental effect on this process. As the pandemic spread, COVID-19 had little beneficial effect on market expansion because of the rising need for genomics technology in the creation of COVID-19 diagnoses and treatments. 
For instance, according to the Canadian Medical Association Journal findings, Researchers saw large reductions in the number of new diagnoses for some cancer types during the SOE period, with a drop of 43% (melanoma), 36% (colorectal and prostate) and 33% (breast). In the post-SOE phase, diagnoses increased by 9%, 8%, and 10% per month, respectively. In Ontario, there was a 34% drop in new cancer diagnoses in April 2020, and Manitoba had a 23% reduction in the same period. An estimated 15% reduction in Quebec occurred in the first year of the pandemic.
Source:(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260240/)

Opportunities for The Pharmacogenomics Market

• The growing adoption of precision medicine is a significant opportunity to drive the pharmacogenomics market growth. 

Precision medicine, sometimes called personalized medicine, is a cutting-edge method of healthcare delivery that tailors medical treatment to each patient according to their unique genetic, genomic, and clinical features. As the industry moves towards more personalized medicine, pharmacogenomics could play a key role in keeping patients healthier longer and in getting them viable treatments for their unique genetic profile. This paradigm shift in healthcare has led to considerable advancements in the pharmacogenomics industry. Modern medicine is evolving as a result of the confluence of pharmacogenomics and personalized medicine, which has opened up new avenues for improving patient outcomes, reducing side events, and optimizing prescription management. The growing adoption of precision medicine is driving the pharmacogenomics industry by increasing therapeutic efficacy. 
For instance, in October 2021, A partnership created to boost precision medicine research in Israel has chosen 11 multidisciplinary projects that will together get some NIS 32 million ($9.9 million) in funding to promote a variety of studies. These include the use of advanced algorithms and artificial intelligence for treating breast cancer and Crohn’s disease, genomic sequencing and analysis for the discovery of new disease genes, and treatments for rare disorders, and advanced machine learning image analysis to profile different cancers.
Source:(https://www.timesofisrael.com/11-israeli-projects-get-millions-in-funding-for-personalized-medicine-research/)

For instance, in May 2024 Recent patents, such as Scorpion Therapeutics Inc.’s inhibitors for cancer treatment and SCV-Spezial-Chemikalien-Vertrieb GmbH’s prostate cancer diagnostic labels, exemplify advancements in targeted therapies. As strategic investments and job growth highlight the importance of this field, the US continues to lead in the adoption and innovation of precision medicine.
Source:(https://www.pharmaceutical-technology.com/data-insights/precision-and-personalized-medicine-in-pharma/?cf-view)
Thus, the growing adoption of precision medicine for the treatment of infectious diseases including HIV/AIDS, TB, and cancer, as well as other disorders, is expected to drive the market over the forecast period.

With the help of the above study about the Pharmacogenomics market, it can be concluded that the market for pharmacogenomics worldwide is expected to develop significantly shortly. From the report, one can understand and infer the market dynamics, segmentations, status and trends, and key players in the market. It provides data regarding various topics such as market dimensions, prevailing trends, competitive landscape, and the outlook for prospective expansion. This allows the reader to understand and access reliable data about the market and industry.

Frequently Asked Questions